S-1/A: CG Oncology Eyes Nasdaq Debut with $289 Million IPO to Advance Bladder Cancer Therapy

CG Oncology is seeking to raise $289 million through an initial public offering to fund the development and commercialization of its bladder cancer therapeutic, cretostimogene.

Summary

• CG Oncology, a late-stage clinical biopharmaceutical company, has filed an amendment to its S-1 registration statement for a proposed initial public offering.
• The company plans to offer 17,000,000 shares of its common stock, with an anticipated initial public offering price between $16.00 and $18.00 per share.
• This offering is contingent upon the approval of listing on the Nasdaq Global Select Market under the symbol CGON.
• The company is focused on developing and commercializing cretostimogene, a potential bladder-sparing therapeutic for patients with bladder cancer.
• Cretostimogene is currently in Phase 3 clinical trials for the treatment of high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy.
• The company expects to report topline data from its ongoing Phase 3 BOND-003 clinical trial by the end of 2024.
• As of the October 5, 2023 efficacy data cutoff, 50 of the 66 (75.7%; 95% CI: 63-85%) evaluable patients achieved a complete response (CR) at any time after the administration of cretostimogene.
• The company also intends to assess the safety and efficacy of cretostimogene in treating a range of other bladder cancer indications.
• The company estimates net proceeds from the offering will be approximately $262.8 million, or $303.1 million if underwriters exercise their over-allotment option in full.
• The company intends to use the net proceeds to fund research and development of cretostimogene and for working capital and other general corporate purposes.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential of the company's lead drug candidate and the risks associated with its development and commercialization. The interim clinical data is promising, but the company's financial history and dependence on a single product candidate introduce significant uncertainty. The sentiment is cautiously optimistic.

Positives

• Cretostimogene has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination with other therapies in clinical trials to date.
• The company has completed enrollment for the BOND-003 trial and expects to report topline data by the end of 2024.
• Cretostimogene has received fast track designation from the FDA for the treatment of BCG-unresponsive, high risk NMIBC patients with carcinoma in-situ with or without Ta or T1 papillary tumors to improve CR.
• The company is backed by a strong set of healthcare-specific investors.
• The company's management team includes industry executives with extensive biopharmaceutical experience.

Negatives

• The company has a relatively limited operating history and has incurred significant operating losses since its inception.
• The company depends entirely on the success of cretostimogene, which is its only product candidate.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company relies on third parties to conduct its clinical trials and preclinical studies and for the manufacture and shipping of cretostimogene.
• The company may be unable to obtain, maintain, and enforce patent or other intellectual property protection for cretostimogene or any future product candidates or technology.

Risks

• The company may never generate any revenue or become profitable.
• The company will require substantial additional capital to finance its operations.
• Cretostimogene or any future product candidates may not achieve favorable results in clinical trials or preclinical studies or receive regulatory approval on a timely basis, if at all.
• Use of cretostimogene or any future product candidates could be associated with adverse side effects, adverse events or other properties or safety risks.
• The company faces significant competition.
• The company relies on third parties to conduct its clinical trials and preclinical studies, and these third parties may not perform satisfactorily.
• The company relies on third parties for the manufacture and shipping of cretostimogene for clinical development.
• If the company is unable to obtain, maintain, and enforce patent or other intellectual property protection for cretostimogene or any future product candidates or technology, its ability to successfully commercialize cretostimogene or any future product candidates, may be adversely affected.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the foreseeable future and anticipates these losses will increase substantially as it continues its development of, seeks regulatory approval for, and potentially commercializes cretostimogene and potentially seeks to discover and develop additional product candidates.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on oncology, particularly bladder cancer. The global bladder cancer treatment market has been forecast to be approximately $9.9 billion by 2028, according to Evaluate Pharma.

Comparison to Industry Standards

• The company's competitors include larger and better-funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies.
• There are numerous companies that have commercialized or are developing treatments for NMIBC that CG Oncology will compete with, including Bristol Meyers Squibb, enGene Inc., Gilead Sciences, Inc., Hoffman-La Roche AG (Roche), ImmunityBio Inc., Johnson & Johnson Inc., Merck, Protara Therapeutics, Inc., Pfizer, Inc. and UroGen Pharma, Inc.
• The company's competitors have developed, are developing or may develop products, product candidates and processes competitive with cretostimogene.
• The company's competitors may be able to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before CG Oncology is able to enter the market.

Management Changes

Related Party Transactions

• The document discloses several related party transactions, including sales of redeemable convertible preferred stock to entities affiliated with directors and significant stockholders, and consulting agreements with entities affiliated with executive officers and directors.

Stakeholder Impact

• The IPO will provide the company with additional capital to advance its clinical programs, potentially benefiting patients with bladder cancer.
• The company's success will depend on its ability to attract and retain qualified management and other clinical and scientific personnel.
• The company's operations and the operations of its manufacturers, suppliers, collaborators, CROs and clinical sites could be subject to earthquakes, power shortages, telecommunications or infrastructure failures, cybersecurity incidents, physical security breaches, water shortages, floods, hurricanes, typhoons, blizzards and other extreme weather conditions, fires, public health pandemics or epidemics (including, for example, the COVID-19 pandemic) and other natural or manmade disasters or business interruptions, for which the company is predominantly self-insured.

Next Steps

• Complete the ongoing BOND-003 Phase 3 trial of cretostimogene as monotherapy in high-risk BCG-unresponsive NMIBC and pursue FDA approval.
• Expand the development of cretostimogene monotherapy as a potential backbone therapy across NMIBC indications.
• Continue to evaluate cretostimogene in combination with other therapies, such as CPIs, to potentially further enhance its clinical utility across various stages of bladder cancer.
• Build operational capabilities to successfully commercialize cretostimogene.
• Leverage chemistry, manufacturing and controls (CMC) expertise and relationships to scale commercialization efforts.

Key Dates

Keywords

cretostimogene, bladder cancer, NMIBC, CG Oncology, clinical trials, biopharmaceutical, BCG-unresponsive, FDA, IPO, oncology